Czobor P, Volavka J, Meibach R C
Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.
J Clin Psychopharmacol. 1995 Aug;15(4):243-9. doi: 10.1097/00004714-199508000-00002.
The objective was to examine effects of risperidone on hostility and compare these effects with those of haloperidol. On the basis of risperidone's pharmacologic profile, we hypothesized that risperidone has a selective effect on hostility and that this effect is greater than that of haloperidol. The data were obtained in a multicenter clinical trial of risperidone under placebo-controlled, double-blind conditions (duration, 9 weeks). The patients were 139 patients with the diagnosis of DSM-III-R schizophrenia. Hostility was measured by the "hostility" item of the Positive and Negative Syndrome Scale. Change in hostility served as a dependent variable in the analyses. Change in "psychosis" was applied as a covariate; it helped us examine changes in hostility that were unrelated to change in psychosis (selective effect). Risperidone had a greater selective effect on hostility than did haloperidol or placebo. This finding should encourage tests of risperidone as a treatment for patients who show frequent overt physical aggression.
目的是研究利培酮对敌意的影响，并将这些影响与氟哌啶醇的影响进行比较。基于利培酮的药理学特征，我们假设利培酮对敌意有选择性作用，且这种作用大于氟哌啶醇。数据来自一项在安慰剂对照、双盲条件下（为期9周）进行的利培酮多中心临床试验。患者为139例诊断为DSM-III-R精神分裂症的患者。敌意通过阳性和阴性症状量表的“敌意”项目进行测量。敌意的变化作为分析中的因变量。“精神病”的变化用作协变量；它帮助我们研究与精神病变化无关的敌意变化（选择性作用）。与氟哌啶醇或安慰剂相比，利培酮对敌意具有更大的选择性作用。这一发现应促使对利培酮作为频繁表现出明显身体攻击行为患者的治疗方法进行测试。
